Literature DB >> 2952464

The effects of aldose reductase inhibitor on the corneal endothelial morphology in diabetic rats.

M Matsuda, T Awata, Y Ohashi, M Inaba, M Fukuda, R Manabe.   

Abstract

Diabetic rats were produced by intravenous injection of streptozotocin. Of these, eleven rats were treated with topical instillation of 0.5% aldose reductase inhibitor (ARI), while ten received vehicle alone. The corneal endothelium of these diabetic rats was examined by specular microscopy and compared to age-matched nondiabetic rats (ten rats). Computerized morphometric analysis of individual cells demonstrated that the endothelium of the untreated diabetic rats had marked polymegathism (increased coefficient of variation in cell area) and pleomorphism (decreased percentage of hexagonal cells), as previously observed in diabetic patients. Similar endothelial changes were also noted in the ARI-treated diabetic rats, but to a significantly lesser extent. These results suggest that topically applied ARI can be effective in reducing morphologic changes of the diabetic endothelium, and that activation of the sorbitol pathway may be implicated in the etiology of such endothelial changes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2952464     DOI: 10.3109/02713688709025192

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  10 in total

1.  Prevention of diabetic keratopathy.

Authors:  Y Kaji
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

2.  Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration.

Authors:  R K Brazzell; C B Wooldridge; R B Hackett; B A McCue
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

3.  Sensory nerve regeneration after epithelium wounding in normal and diabetic cornea.

Authors:  Fu-Shin Yu; Jia Yin; Patrick Lee; Frank S Hwang; Mark McDermott
Journal:  Expert Rev Ophthalmol       Date:  2015-06-26

Review 4.  Sorbitol, osmoregulation, and the complications of diabetes.

Authors:  M B Burg; P F Kador
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

5.  Topical aldose reductase inhibitor.

Authors:  D Coster
Journal:  Br J Ophthalmol       Date:  1995-12       Impact factor: 4.638

6.  Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.

Authors:  H Fujishima; K Tsubota
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

7.  Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients.

Authors:  N Ohguro; M Matsuda; Y Ohashi; M Fukuda
Journal:  Br J Ophthalmol       Date:  1995-12       Impact factor: 4.638

8.  The effect of long-term topical administration of commercial beta-blockers on the rat corneal endothelium.

Authors:  M Matsuda; Y Ishii; T Awata; M Fukuda
Journal:  Int Ophthalmol       Date:  1989-01       Impact factor: 2.031

9.  Clinical evaluation of corneal changes after phacoemulsification in diabetic and non-diabetic cataract patients, a systematic review and meta-analysis.

Authors:  Yizhen Tang; Xinyi Chen; Xiaobo Zhang; Qiaomei Tang; Siyu Liu; Ke Yao
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

10.  Active-fluidics-based torsional phacoemulsification in diabetic eyes: A prospective interventional study.

Authors:  Sudarshan Khokhar; Sagnik Sen; Chirakshi Dhull
Journal:  Indian J Ophthalmol       Date:  2019-05       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.